Trial Profile
Prospective safety and immunogenicity study of GV1001 (tertomotide), Granulocyte macrophage colony stimulating factor (GM-CSF) and gemcitabine administered to pancreatic cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Tertomotide (Primary) ; Gemcitabine; Granulocyte macrophage colony stimulating factor
- Indications Pancreatic cancer
- Focus Adverse reactions
- 05 Nov 2015 New trial record